14,585 results match your criteria Hepatocellular Carcinoma Imaging


Deep learning for liver tumor diagnosis part I: development of a convolutional neural network classifier for multi-phasic MRI.

Eur Radiol 2019 Apr 23. Epub 2019 Apr 23.

Department of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.

Objectives: To develop and validate a proof-of-concept convolutional neural network (CNN)-based deep learning system (DLS) that classifies common hepatic lesions on multi-phasic MRI.

Methods: A custom CNN was engineered by iteratively optimizing the network architecture and training cases, finally consisting of three convolutional layers with associated rectified linear units, two maximum pooling layers, and two fully connected layers. Four hundred ninety-four hepatic lesions with typical imaging features from six categories were utilized, divided into training (n = 434) and test (n = 60) sets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-019-06205-9DOI Listing
April 2019
2 Reads

Nonalcoholic fatty liver disease: an update on the diagnosis.

Gene Expr 2019 Apr 22. Epub 2019 Apr 22.

Institute of Model Animals of Wuhan University, Wuhan, China.

Nonalcoholic fatty liver disease (NAFLD) is a common liver disease and a major cause of related complications such as cirrhosis and hepatocellular carcinoma (HCC). NAFLD progresses through the stages of simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis and HCC. However, NAFLD usually cannot be diagnosed in a timely manner, which is largely attributed to the asymptomatic features of NAFLD patients and the lack of an effective and accurate noninvasive screening approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3727/105221619X15553433838609DOI Listing

Elevated non-invasive liver fibrosis markers and risk of liver carcinoma in adult patients after repair of tetralogy of Fallot.

Int J Cardiol 2019 Apr 11. Epub 2019 Apr 11.

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

Background: Congestive hepatopathy and hepatocellular carcinoma is a serious complication after Fontan procedure. Liver fibrosis due to hepatic congestion could occur also in adult patients after repair of tetralogy of Fallot (rTOF). However, the incidence and severity remain unclear. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01675273183676
Publisher Site
http://dx.doi.org/10.1016/j.ijcard.2019.04.032DOI Listing
April 2019
1 Read

Using principal component analysis for the prediction of tumor response to transarterial chemoembolization.

Abdom Radiol (NY) 2019 Apr 19. Epub 2019 Apr 19.

Department of Interventional Radiology, Washington University School of Medicine, 510 S. Kingshighway Blvd, St. Louis, MO, 63110, USA.

Purpose: To quantitate the tumor blush of hepatocellular carcinoma (HCC) at the time of transarterial chemoembolization (TACE) using principal component analysis (PCA), and to correlate the quantitated tumor blush to response to therapy.

Materials And Methods: In this proof-of-concept study, 27 primary HCC tumors in 25 patients (18 men, 7 women; mean age 66 years ± 9) were analyzed. We conducted a retrospective analysis of TACE procedures that were performed during March through July of 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-01982-9DOI Listing

Co-assembled Ca Alginate-Sulfate Nanoparticles for Intracellular Plasmid DNA Delivery.

Mol Ther Nucleic Acids 2019 Mar 28;16:378-390. Epub 2019 Mar 28.

Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel; Regenerative Medicine and Stem Cell (RMSC) Research Center, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel; The Ilse Katz Institute for Nanoscale Science and Technology, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel. Electronic address:

Successful gene therapy requires the development of suitable carriers for the selective and efficient delivery of genes to specific target cells, with minimal toxicity. In this work, we present a non-viral vector for gene delivery composed of biocompatible materials, CaCl, plasmid DNA and the semi-synthetic anionic biopolymer alginate sulfate (AlgS), which spontaneously co-assembled to form nanoparticles (NPs). The NPs were characterized with a slightly anionic surface charge (Zeta potential [ζ] = -14 mV), an average size of 270 nm, and their suspension was stable for several days with no aggregation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21622531193006
Publisher Site
http://dx.doi.org/10.1016/j.omtn.2019.03.006DOI Listing
March 2019
2 Reads

Sorafenib Induces Pyroptosis in Macrophages and Triggers NK Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma.

Hepatology 2019 Apr 19. Epub 2019 Apr 19.

Roche Innovation Center Munich, Roche Pharma Research and Early Development, Nonnenwald 2, 82377, Penzberg, Germany.

Antiangiogenic and cytotoxic effects are referred as the principle mechanisms of action of sorafenib, a multi-target kinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC). Here we report, that sorafenib also acts via direct immune-modulation indispensable for its anti-tumor activity. In vivo cell depletion experiments in two orthotopic HCC mouse models as well as in vitro analysis identified macrophages (MΦ) as the key mediators of the anti-tumoral effect and demonstrate a strong interdependency of MΦ and natural killer (NK) cells for efficient tumor cell killing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30666DOI Listing

Early experience of combination therapy of transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma measuring 3-7 cm.

Indian J Radiol Imaging 2019 Jan-Mar;29(1):47-52

Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.

Background Of The Article: Hepatocellular carcinoma (HCC) is one of the most common human malignancies worldwide. Radiofrequency ablation (RFA) is considered curative option in selected patients; efficacy is severely limited by lesion size and lesions bordering a large vessel. On the other hand, transarterial chemoembolization (TACE) is not limited by lesion size and arterial occlusion of the tumor feeding vessels leads to increase the volume of the ablative zone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijri.IJRI_352_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467046PMC

Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation.

BMC Cancer 2019 Apr 18;19(1):364. Epub 2019 Apr 18.

Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, 58th, The Second Zhongshan Road, Guangzhou, 510080, Guangdong, China.

Background: Our aim of the study is to investigate the feasibility of preoperative prediction for hepatocellular carcinoma (HCC) histological grading using gadoxetic acid-enhanced magnetic resonance imaging (MRI).

Methods: This study included one hundred and fifty-six patients with solitary HCC. Preoperative gadoxetic acid-enhanced MRI findings were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5574-8DOI Listing

Current status of nanomaterial-based treatment for hepatocellular carcinoma.

Biomed Pharmacother 2019 Apr 15;116:108852. Epub 2019 Apr 15.

Departments of Biology, UAE University, Al Ain, United Arab Emirates. Electronic address:

Cancer continues to be the leading cause of death worldwide. Hepatocellular carcinoma (HCC), a prominent form of liver cancer, is the second leading cause of cancer-related deaths, thanks to the lack of efficient diagnostic tools and consequently late diagnosis and to the scarce of available suitable treatments. Thus, novel approaches to treat HCC are in demand. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07533322183881
Publisher Site
http://dx.doi.org/10.1016/j.biopha.2019.108852DOI Listing
April 2019
1 Read

Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma.

AJR Am J Roentgenol 2019 Apr 17:1-9. Epub 2019 Apr 17.

1 Centre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada.

The purpose of this study is to compare imaging-based surveillance and diagnostic strategies in patients at risk for hepatocellular carcinoma (HCC) while taking into account technically inadequate examinations and patient compliance. A Markov model simulated seven strategies for HCC surveillance and diagnosis in patients with cirrhosis: strategy A, ultrasound (US) for surveillance and CT for diagnosis; strategy B, US for surveillance and complete MRI for diagnosis; strategy C, US for surveillance and CT for inadequate or positive surveillance; strategy D, US for surveillance and complete MRI for inadequate or positive surveillance; strategy E, surveillance and diagnosis with CT followed by complete MRI for inadequate surveillance; strategy F, surveillance and diagnosis with complete MRI followed by CT for inadequate surveillance; and strategy G, surveillance with abbreviated MRI followed by CT for inadequate surveillance or complete MRI for positive surveillance. Two compliance scenarios were evaluated: optimal and conservative. Read More

View Article

Download full-text PDF

Source
https://www.ajronline.org/doi/10.2214/AJR.18.20341
Publisher Site
http://dx.doi.org/10.2214/AJR.18.20341DOI Listing
April 2019
1 Read

Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation.

Eur Radiol 2019 Apr 16. Epub 2019 Apr 16.

State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, China.

Objective: To study lipiodol deposition in portal vein tumour thrombus (PVTT) in predicting the treatment outcome of hepatocellular carcinoma (HCC) patients after transarterial chemoembolisation (TACE).

Methods: We retrospectively reviewed data from 379 HCC patients with PVTT who underwent TACE as the initial treatment at Sun Yat-Sen University Cancer Center from January 2008 to December 2015. Patients were grouped by positive and negative lipiodol deposition based on the extent of lipiodol deposition in PVTT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-019-06157-0DOI Listing

Modified CAIPIRINHA-VIBE without view-sharing on gadoxetic acid-enhanced multi-arterial phase MR imaging for diagnosing hepatocellular carcinoma: comparison with the CAIPIRINHA-Dixon-TWIST-VIBE.

Eur Radiol 2019 Apr 16. Epub 2019 Apr 16.

Department of Radiology, Biomedical Research Institute, Pusan National University Yangsan Hospital, and Pusan National University School of Medicine, Busan, South Korea.

Purpose: We evaluated the detection rate and degree of motion artifact of the modified CAIPIRINHA-VIBE (mC-VIBE) without view-sharing and compare them with the CAIPIRINHA-Dixon-TWIST-VIBE (CDT-VIBE) with view-sharing on multi-arterial gadoxetic acid-enhanced liver MRI in the assessment of hepatocellular carcinoma (HCC).

Material And Methods: We retrospectively identified 114 pathological-proven hepatic tumors in 114 patients with risk of HCC who underwent multi-arterial gadoxetic acid-enhanced MRI between June 2016 and June 2018. All patients underwent triple arterial phase imaging using the mC-VIBE without view-sharing (54 patients; 49 HCCs and 5 non-HCCs) or the CDT-VIBE with view-sharing (60 patients; 55 HCCs and 5 non-HCCs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-019-06095-xDOI Listing

Gadoxetic Acid-enhanced MRI of Hepatocellular Carcinoma: Value of Washout in Transitional and Hepatobiliary Phases.

Radiology 2019 Apr 16:182587. Epub 2019 Apr 16.

From the Department of Radiology and Research Institute of Radiology (D.H.K., S.H.C., S.Y.K., S.S.L., J.H.B.) and Department of Clinical Epidemiology and Biostatistics (M.J.K.), University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul 05505, Republic of Korea.

Background Current Liver Imaging Reporting and Data System guidelines define the washout appearance of gadoxetic acid-enhanced MRI only during the portal venous phase. Defining washout only during the portal venous phase may lead to lower sensitivity for diagnosis of hepatocellular carcinoma (HCC). Purpose To compare the diagnostic performances of three gadoxetic acid-enhanced MRI criteria fono. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2019182587DOI Listing
April 2019
1 Read

Recent advances in PET probes for hepatocellular carcinoma characterization.

Expert Rev Med Devices 2019 Apr 16. Epub 2019 Apr 16.

a Department of Nuclear Medicine , Santa Maria Goretti Hospital , Via Canova 3, 04100 Latina , Italy.

Introduction: Positron Emission Tomography (PET) with F-fluorodeoxyglucose (FDG) presents some limitations for imaging of hepatocellular carcinoma (HCC), the most common primary hepatic malignancy. Areas covered: The authors discuss the accuracy and limitations of FDG for HCC detection. Then, authors examine the recent advances in PET tracers other than FDG for the biological and prognostic characterization of HCC such as C-acetate, C-choline and its F-labeled derivatives. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17434440.2019.1
Publisher Site
http://dx.doi.org/10.1080/17434440.2019.1608817DOI Listing
April 2019
3 Reads

ALBI/ST ratio versus FIB-4 and APRI as a predictor of posthepatectomy liver failure in hepatocellular carcinoma patients.

Medicine (Baltimore) 2019 Apr;98(15):e15168

Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

A precise and noninvasive method to predict posthepatectomy liver failure (PHLF) in clinical practice is still lacking. Liver fibrosis or cirrhosis accompanied with varying degrees of portal hypertension plays an important role in the occurrence of PHLF in hepatocellular carcinoma (HCC) patients. This study aims to compare the predictive ability of the albumin-bilirubin score to spleen thickness ratio (ALBI/ST) versus fibrosis-4 index (FIB-4) and aspartate aminotransferase to platelet count ratio index (ARPI) for the occurrence of PHLF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015168DOI Listing
April 2019
1 Read

Feasibility of hyperspectral analysis for discrimination of rabbit liver VX2 tumor.

World J Gastrointest Oncol 2019 Jan;11(1):1-8

Key Laboratory of Spectral Imaging Technology of Chinese Academy of Sciences, Xi'an Institute of Optics and Precision Mechanics, Chinese Academy of Sciences, Xi'an 710119, Shaanxi Province, China.

Background: Hepatocellular carcinoma is one of the most common malignant tumors worldwide. Currently, the most accurate diagnosis imaging modality for hepatocellular carcinoma is enhanced magnetic resonance imaging. However, it is still difficult to distinguish cirrhosis lesions, and novel diagnosis modalities are still needed. Read More

View Article

Download full-text PDF

Source
https://www.wjgnet.com/1948-5204/full/v11/i1/1.htm
Publisher Site
http://dx.doi.org/10.4251/wjgo.v11.i1.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451930PMC
January 2019
2 Reads

Hepatocellular carcinoma surveillance: An evidence-based approach.

World J Gastroenterol 2019 Apr;25(13):1550-1559

Division of Gastroenterology and Hepatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, United States.

Hepatocellular carcinoma (HCC) makes up 75%-85% of all primary liver cancers and is the fourth most common cause of cancer related death worldwide. Chronic liver disease is the most significant risk factor for HCC with 80%-90% of new cases occurring in the background of cirrhosis. Studies have shown that early diagnosis of HCC through surveillance programs improve prognosis and availability of curative therapies. Read More

View Article

Download full-text PDF

Source
https://www.wjgnet.com/1007-9327/full/v25/i13/1550.htm
Publisher Site
http://dx.doi.org/10.3748/wjg.v25.i13.1550DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452232PMC
April 2019
4 Reads

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Aliment Pharmacol Ther 2019 May 12;49(10):1323-1333. Epub 2019 Apr 12.

Vienna, Austria.

Background: Programmed cell death protein-1-targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma.

Aim: To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real-world cohort of patients with advanced hepatocellular carcinoma.

Methods: Sixty-five patients treated with nivolumab (n = 34) or pembrolizumab (n = 31) between July 10, 2015 and December 31, 2018 (data cut-off) across six centres in Austria and Germany were retrospectively analysed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15245DOI Listing
May 2019
1 Read

Polyploidy spectrum: a new marker in HCC classification.

Gut 2019 Apr 12. Epub 2019 Apr 12.

Team Proliferation Stress and Liver Physiopathology, Genome and Cancer, Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France.

Objectives: Polyploidy is a fascinating characteristic of liver parenchyma. Hepatocyte polyploidy depends on the DNA content of each nucleus (nuclear ploidy) and the number of nuclei per cell (cellular ploidy). Which role can be assigned to polyploidy during human hepatocellular carcinoma (HCC) development is still an open question. Read More

View Article

Download full-text PDF

Source
http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2018-318021
Publisher Site
http://dx.doi.org/10.1136/gutjnl-2018-318021DOI Listing
April 2019
9 Reads

Transcatheter arterial embolization as palliation in metastatic hepatocellular carcinoma.

Pediatr Blood Cancer 2019 Apr 12:e27754. Epub 2019 Apr 12.

Department of Pediatrics, University of California San Diego, San Diego, California.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.27754
Publisher Site
http://dx.doi.org/10.1002/pbc.27754DOI Listing
April 2019
4 Reads
2.562 Impact Factor

Can IVIM help predict HCC recurrence after hepatectomy?

Eur Radiol 2019 Apr 10. Epub 2019 Apr 10.

Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University (SYSU), No 600, Tianhe Road, Guangzhou, 510630, People's Republic of China.

Purpose: To determine the diagnostic performance of intravoxel incoherent motion (IVIM) parameters to predict tumor recurrence after hepatectomy in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).

Materials And Methods: One hundred and fifty-seven patients (mean age 52.54 ± 11. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-019-06180-1DOI Listing
April 2019
1 Read

Treatment selection of recurrent hepatocellular carcinoma with microvascular invasion at the initial hepatectomy.

Am J Transl Res 2019 15;11(3):1864-1875. Epub 2019 Mar 15.

Department of Medical Imaging, Sun Yat-sen University Cancer Center 651 Dongfeng Road East, Guangzhou, China.

Background: Recurrent hepatocellular carcinoma (rHCC) patients with microvascular invasive (MVI) positive at first resection usually had poorly differentiated tumors and worse survivals. The optimal treatment for this population remains to be elucidated.

Methods: We retrospectively analyzed 319 rHCC patients with MVI-positive at first resection from June, 2009 to June, 2017. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456518PMC
March 2019
1 Read

Radiomics and its advances in hepatocellular carcinoma.

Zhong Nan Da Xue Xue Bao Yi Xue Ban 2019 Mar;44(3):225-232

Department of Radiology, Muhimbili National Hospital, Dar es Salaam 65000, Tanzania.

Liver cancer is the second leading cause of cancer-related death worldwide, so early detection and prediction for response to treatment is of great benefit to hepatocellular carcinoma (HCC) patients. Currently, needle biopsy and conventional medical imaging play a significant and basic role in HCC patients' management, while those two approaches are limited in sample error and observer-dependence. Radiomics can make up for this deficiency because it is an emerging non-invasive technic that is capable of getting comprehensive information relevant to tumor situation across spatial-temporal limitation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11817/j.issn.1672-7347.2019.03.001DOI Listing

Is liver lesion characterisation by simplified IVIM DWI also feasible at 3.0 T?

Eur Radiol 2019 Apr 8. Epub 2019 Apr 8.

Department of Radiology, University of Bonn, Bonn, Germany.

Objective: To evaluate simplified intravoxel incoherent motion (IVIM) diffusion-weighted imaging (DWI) for liver lesion characterisation at 3.0 T and to compare it with 1.5 T. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-019-06192-xDOI Listing

Polyethylenimine (PEI)-Mediated E1A Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy.

Med Sci Monit Basic Res 2019 Apr 8;25:113-120. Epub 2019 Apr 8.

Department of Radiotherapy, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China (mainland).

BACKGROUND The aim of this study was to assess the ability of polyethylenimine (PEI) as an E1A plasmid vector to transfect hepatocellular carcinoma SMMC-7721 cells and to analyze the sensitization effect of E1A on various anti-tumor drugs. MATERIAL AND METHODS PEI-mediated recombinant plasmid psv-E1A with high expression of the E1A gene was introduced into hepatocellular carcinoma SMMC-7721 cells, and the effective transfection of E1A gene was determined by RT-PCR and Western blot analysis. The CCK8 method was used to detect the proliferation inhibition of docetaxel, epirubicin, gemcitabine, and 5-fluorouracil on SMMC-7721 cells before and after the transfection of the E1A gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSMBR.914811DOI Listing
April 2019
2 Reads

Hepatic disorders associated with exogenous sex steroids: MR imaging findings.

Abdom Radiol (NY) 2019 Apr 6. Epub 2019 Apr 6.

Monash Imaging, Monash Health, Melbourne, Australia.

Objective: To describe the MRI findings of the effects of exogenous sex steroids on the liver.

Findings: Estrogens, progesterone and synthetic testosterone are exogenous sex steroids that may result in a variety of liver diseases, including tumour formation and vascular disorders. These hormones are mainly administered in the form of the oral contraceptive pill (OCP) and anabolic steroids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-01941-4DOI Listing
April 2019
2 Reads

Holmium-166 Microsphere Radioembolization of Hepatic Malignancies.

Semin Nucl Med 2019 May 1;49(3):237-243. Epub 2019 Feb 1.

University Medical Center Utrecht (UMCU), Utrecht, Netherlands.

Holmium microspheres have recently become available in the European market as the third type of microspheres for radioembolization of unresectable liver malignancies. Holmium microspheres come with a dedicated administration system, and since these microspheres contain holmium-166 (Ho) instead of yttrium-90, unique dosing and imaging possibilities have become available as well. In addition, a scout dose of Ho microspheres (Conformité Européenne mark is now granted and not pending anymore) can be used instead of Tc-macroaggragated albumin during the preparatory angiography procedure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semnuclmed.2019.01.008DOI Listing

A 12-year Recurrence-free Survival After Multidisciplinary Treatment for a Patient With Combined Hepatocellular-Cholangiocarcinoma.

Anticancer Res 2019 Apr;39(4):2139-2144

Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan.

We report a 64-year-old woman with a 9-cm liver tumor in the left lateral section. The patient had neither hepatitis B or C virus infection, nor cirrhosis. Carbohydrate antigen 19-9 (CA 19-9) level was 1,889 U/ml. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13327DOI Listing
April 2019
2 Reads

Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study.

Can J Gastroenterol Hepatol 2019 5;2019:8747438. Epub 2019 Mar 5.

Department of Hepatobiliary and Transplant Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Selection and prioritization of patients with HCC for LT are based on pretransplant imaging diagnostic, taking the risk of incorrect diagnosis. According to the German waitlist guidelines, imaging has to be reported to the allocation organization (Eurotransplant) and pathology reports have to be submitted thereafter. In order to assess current procedures we performed a retrospective multicenter analysis in all German transplant centers with focus on accuracy of imaging diagnostic and tumor classification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8747438DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425358PMC
March 2019
2 Reads

Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma.

World J Clin Oncol 2019 Mar;10(3):149-160

Roche and Teclison Pharmaceutical Company, Montclair, NJ 07042, United States.

Background: Hypoxia-inducible factor 1α (HIF-1α) is a gene that regulates tumor survival, neovascularization and invasion. Overexpression of HIF-1α correlates with poor prognosis in hepatocellular carcinoma (HCC). RO7070179 is a HIF-1α inhibitor that decreases HIF-1α mRNA and its downstream targets, it could be a potential treatment in HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5306/wjco.v10.i3.149DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441661PMC
March 2019
1 Read

Value of F-FDG PET/CT in the diagnosis of portal vein tumor thrombus in patients with hepatocellular carcinoma.

Abdom Radiol (NY) 2019 Apr 3. Epub 2019 Apr 3.

Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Xuhui District, Shanghai, China.

Objective: The aim of this study was to evaluate the usefulness of F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) for the diagnosis of a portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma (HCC).

Methods: One hundred fifty-four patients with histologically proven HCC underwent F-FDG PET/CT imaging. The maximum standardized uptake value (SUVmax) was calculated, and the change in SUVmax (retention index, RI) was defined as the ratio of the increase in SUVmax between early and delayed scans to the SUVmax in the early scan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-01997-2DOI Listing

Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances.

J Clin Transl Hepatol 2019 Mar 17;7(1):72-85. Epub 2019 Feb 17.

Department of Radiology, Mayo Clinic, Rochester, MN, USA.

The incidence of hepatocellular carcinoma (HCC) is increasing, with this trend expected to continue to the year 2030. Hepatocarcinogenesis follows a predictable course, which makes adequate identification and surveillance of at-risk individuals central to a successful outcome. Moreover, imaging is central to this surveillance, and ultimately to diagnosis and management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14218/JCTH.2018.00032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441649PMC

Polydatin inhibits hepatocellular carcinoma via the AKT/STAT3-FOXO1 signaling pathway.

Oncol Lett 2019 May 7;17(5):4505-4513. Epub 2019 Mar 7.

Department of Abdominal Ultrasonography, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.

Polydatin, extracted from , is known for its anti-platelet aggregation and anti-inflammatory effects. However, studies on the association of polydatin with cancer are limited, particularly with regards to epithelial-mesenchymal transition (EMT)-associated migration and invasion of cancer cells. The purpose of the present study was to reveal the potential anticancer effects of polydatin on hepatocellular carcinoma (HCC) cells, particularly its effects on EMT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2019.10123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444395PMC
May 2019
2 Reads

Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience.

Dig Dis Sci 2019 Apr 1. Epub 2019 Apr 1.

Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia, 80138, Naples, Italy.

Purpose: The aim of this study was to evaluate the relationship between the liver stiffness measurement and the risk of developing hepatocellular carcinoma (HCC) in HCV cirrhotic patients undergoing new direct-acting antivirals.

Methods: From April 2015 to April 2017, all consecutive HCV cirrhotic patients treated by direct-acting antivirals were enrolled. A liver stiffness measurement was computed at baseline, and an ultrasound evaluation was provided for all patients at baseline and every 6 months until 1 year after the stopping of the antiviral therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-019-05604-8DOI Listing
April 2019
1 Read

Non-contrast MR lymphography of the lymphatic system of the liver.

Eur Radiol 2019 Apr 1. Epub 2019 Apr 1.

Faculté de Médecine Pierre et Marie Curie and Department of Radiology, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, 184 Rue du Faubourg Saint-Antoine, 75012, Paris, France.

This review shows the images obtained with non-contrast MR lymphography in different pathologic conditions affecting the liver. Non-contrast MR lymphography is obtained with a free-breathing 3D high spatial resolution fast-recovery fast spin-echo sequence similar to that used for 3D MR cholangiopancreatography. The liver is the largest lymph-producing organ generating approximately half of the body's lymphatic fluid and is the most important part of the lymphatic system from a functional point of view. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-019-06151-6DOI Listing
April 2019
4 Reads

Downregulation of nucleolar and spindle-associated protein 1 expression suppresses liver cancer cell function.

Exp Ther Med 2019 Apr 26;17(4):2969-2978. Epub 2019 Feb 26.

Nantong Institute of Liver Disease, Nantong Third People's Hospital, Nantong University, Nantong, Jiangsu 226006, P.R. China.

The aim of the present study was to determine the role of nucleolar and spindle-associated protein 1 (NuSAP1) in human liver cancer. NuSAP1 expression was determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR), western blotting and immunohistochemistry in hepatocellular carcinoma (HCC) and adjacent tissues. The expression of NuSAP1 gene was detected by RT-qPCR in liver cancer cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2019.7314DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434240PMC
April 2019
1 Read

A novel theranostic gold nanorods- and Adriamycin-loaded micelle for EpCAM targeting, laser ablation, and photoacoustic imaging of cancer stem cells in hepatocellular carcinoma.

Int J Nanomedicine 2019 13;14:1877-1892. Epub 2019 Mar 13.

Department of Industrial Chemistry "Toso Montanari", Bologna, Italy,

Introduction And Purpose: Cancer stem cells (CSCs) present a higher capacity to evade being killed by cancer agents and developing chemoresistance, thus leading to failure of conventional anticancer therapeutics. Nanomaterials specifically designed for targeting and treating not only tumor cells, but also CSCs, may encompass therapeutic and diagnostic tools, thus successfully eradicating the tumor.

Materials And Methods: Polymeric micelles simultaneously loaded with gold nanorods (GNRs) and Adriamycin were prepared and used as a novel therapeutic and diagnostic weapon. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/a-novel-theranostic-gold-nanorods-
Publisher Site
http://dx.doi.org/10.2147/IJN.S197265DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422422PMC
March 2019
7 Reads

Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma.

Radiother Oncol 2019 Apr 16;133:54-61. Epub 2019 Jan 16.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. Electronic address:

Background And Purpose: This study documents the utilization and efficacy of proton beam therapy (PBT) in western patients with localized unresectable hepatocellular carcinoma (HCC).

Methods And Methods: Forty-six patients with HCC, Child-Pugh class of A or B, no prior radiotherapy history, and ECOG performance status 0-2 received PBT at our institution from 2007 to 2016. Radiographic control within the PBT field (local control, LC) and overall survival (OS) were calculated from the start of PBT. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01678140183367
Publisher Site
http://dx.doi.org/10.1016/j.radonc.2018.10.041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446916PMC
April 2019
5 Reads

Microwave Responsive Nanoplatform via P-Selectin Mediated Drug Delivery for Treatment of Hepatocellular Carcinoma with Distant Metastasis.

Nano Lett 2019 Apr 19. Epub 2019 Apr 19.

Department of Interventional Ultrasound , Chinese PLA General Hospital , Beijing 100853 , China.

Hepatocellular carcinoma (HCC) with metastatic disease is associated with a low survival in clinical practice. Many curative options including liver resection, transplantation, and thermal ablation are effective in local but limited for patients with distant metastasis. In this study, the efficacy, specificity, and safety of P-selectin targeted delivery and microwave (MW) responsive drug release is investigated for development of HCC therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.nanolett.8b05202DOI Listing
April 2019
2 Reads
13.592 Impact Factor

[The comparison among the guidelines for the diagnosis and treatment of hepatocellular carcinoma in China, AASLD and EASL].

Authors:
X H Li L Wei

Zhonghua Gan Zang Bing Za Zhi 2019 Mar;27(3):236-240

Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy of Liver Diseases, Beijing 100044, China.

This article makes a comparative analysis of the key recommendations in surveillance, diagnosis, staging and treatment for hepatocellular carcinoma(HCC) from the newest updated guidelines issued by American Association for the Study Liver Disease, European Association for the Study of Liver, and Chinese Society of Clinical Oncology, respectively. It is agreed that patients at high risk for developing HCC should undergo surveillance with ultrasound every six months. Detected hepatic nodules should be diagnosed and followed-up by further imaging examination or liver biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.1007-3418.2019.03.015DOI Listing
March 2019
2 Reads

Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.

Cancer Lett 2019 Jul 27;453:74-83. Epub 2019 Mar 27.

CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China; Beijing Key Laboratory of Molecular Imaging, Beijing, 100190, China; University of Chinese Academy of Sciences, Beijing, 100080, China; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine, Beihang University, Beijing, 100191, China; Engineering Research Center of Molecular and Neuro Imaging of Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 710126, China. Electronic address:

Sorafenib has been used as a clinical targeted therapy for hepatocellular carcinoma (HCC) for more than a decade. In 2017, regorafenib was approved for HCC treatment and has since been reported to prolong the survival of advanced HCC patients after treatment failure with sorafenib. However, there has been no direct systematic comparison of the therapeutic effects of regorafenib and sorafenib against HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.03.037DOI Listing
July 2019
1 Read

Fontan-associated liver disease: A review.

J Cardiol 2019 Mar 27. Epub 2019 Mar 27.

Adolescent and Adult Congenital Program, Children's Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

The Fontan procedure has led to increased long-term survival of patients with single ventricle congenital heart disease. Hemodynamic changes associated with the Fontan circulation, including elevated central venous pressure and diminished cardiac output are responsible for the development of Fontan-associated liver disease (FALD). Liver fibrosis is a universal feature following the Fontan operation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jjcc.2019.02.016DOI Listing
March 2019
2 Reads

Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma.

Radiol Clin North Am 2019 May 14;57(3):563-583. Epub 2019 Feb 14.

Department of Radiology, Stanford University Medical Center, 300 Pasteur Drive H1307, Stanford, CA 94305, USA.

In the context of chronic liver disease (CLD), sonographic features of hepatic steatosis, cirrhosis, and portal hypertension are discussed and examples are provided. The impact of CLD and hepatocellular carcinoma (HCC) is introduced, providing the rationale for a robust HCC screening and surveillance program for at-risk patients. The American College of Radiology Liver Imaging Reporting and Data System algorithms for screening and surveillance by ultrasound and for the definitive diagnosis of HCC by contrast-enhanced ultrasound are explained, with imaging examples provided. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rcl.2019.01.004DOI Listing
May 2019
1 Read

MR features based on LI-RADS identify cytokeratin 19 status of hepatocellular carcinomas.

Eur J Radiol 2019 Apr 31;113:7-14. Epub 2019 Jan 31.

Department of Radiology, Zhongshan Hospital, Fudan University, and Shanghai Medical Imaging Institute, Shanghai, China. Electronic address:

Objective: To retrospectively evaluate the value of MR features based on Liver Imaging Reporting and Data System (LI-RADS ver.2017) for identifying the status of cytokeratin (CK) 19 expression of HCC before surgery.

Methods: A total of 201 patients with 207 HCCs who underwent MR imaging were reviewed retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2019.01.036DOI Listing
April 2019
2 Reads

Detect or not to detect very early stage hepatocellular carcinoma? The western perspective.

Authors:
Ju Dong Yang

Clin Mol Hepatol 2019 Mar 29. Epub 2019 Mar 29.

Division of Digestive and Liver Diseases, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.

Very early stage hepatocellular carcinoma (HCC) is defined as a single tumor with the largest diameter of the lesion measuring 2 cm or less according to Barcelona Liver Cancer staging system. Detection of very early stage HCC is clinically important as it confers an excellent prognosis with the 5-year survival rates over 60 to 80% after patients receive curative treatments. While diagnosing HCC at a very early stage is crucial, it is technically challenging and may come with the physical or psychosocial harms related to diagnostic tests. Read More

View Article

Download full-text PDF

Source
http://www.e-cmh.org/journal/view.php?doi=10.3350/cmh.2019.0
Publisher Site
http://dx.doi.org/10.3350/cmh.2019.0010DOI Listing
March 2019
2 Reads

LncRNA PAPAS promotes hepatocellular carcinoma by interacting with miR-188-5p.

J Cell Biochem 2019 Mar 28. Epub 2019 Mar 28.

Ultrasound Department of Shandong Provincial Medical Imaging Research Institute, Jinan, Shandong, China.

It has been observed that long noncoding RNA (lncRNA) PAPAS regulates rRNA synthesis, but its role in human diseases is unclear. Our study was carried out to investigate the role of PAPAS in hepatocellular carcinoma (HCC). In the present study, we found that PAPAS was upregulated both in plasma from patients with HCC and tumors compared with plasma from healthy people and tumor-adjacent healthy tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.28623DOI Listing
March 2019
1 Read
3.263 Impact Factor

Identification of an eight-gene signature for survival prediction for patients with hepatocellular carcinoma based on integrated bioinformatics analysis.

PeerJ 2019 20;7:e6548. Epub 2019 Mar 20.

Institute of Tropical Agriculture and Forestry, Hainan University, Hainkou, China.

Background: Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related death worldwide. Despite recent advances in imaging techniques and therapeutic intervention for HCC, the low overall 5-year survival rate of HCC patients remains unsatisfactory. This study aims to find a gene signature to predict clinical outcomes in HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7717/peerj.6548DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431139PMC
March 2019
1 Read

Inactive hepatitis B carriers: outcomes of patients followed at Hôpital Principal de Dakar, Senegal.

Pan Afr Med J 2018 20;31:49. Epub 2018 Sep 20.

Department of Internal Medicine and Hepato-Gastroenterology, Hôpital Principal de Dakar, Dakar, Senegal.

The evolutive profile of inactive HBV carriers is variable. Patients can remain inactive, or may evolve into chronic active hepatitis or hepatocellular carcinoma. Aim: to describe the long-term outcome of chronic hepatitis B inactive carriers followed at Hôpital Principal de Dakar. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11604/pamj.2018.31.49.16296DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430837PMC
April 2019
1 Read

Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.

World J Gastroenterol 2019 Mar;25(11):1307-1326

Department of Cardiology, Renmin Hospital of Wuhan University, Institute of Model Animal of Wuhan University, Wuhan 430071, Hubei Province, China.

With the increasing number of individuals with diabetes and obesity, nonalcoholic fatty liver disease (NAFLD) is becoming increasingly prevalent, affecting one-quarter of adults worldwide. The spectrum of NAFLD ranges from simple steatosis or nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). NAFLD, especially NASH, may progress to fibrosis, leading to cirrhosis and hepatocellular carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v25.i11.1307DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429343PMC

Laparoscopic Hepatectomy (with or without Robotic Assistance) versus Radiofrequency Ablation as a Minimally Invasive Treatment for Very Early-Stage or Early-Stage Hepatocellular Carcinoma.

Dig Surg 2019 Mar 27:1-7. Epub 2019 Mar 27.

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.

Background: The advantages of radiofrequency ablation (RFA) over hepatectomy as a treatment for early-stage hepatocellular carcinoma (HCC) include reduced morbidity and more rapid recovery. Although minimally invasive surgery provides similar benefits, few studies have compared the long-term oncological outcomes of these techniques. This study aimed to compare the outcomes of minimally invasive hepatectomy (MIH) and RFA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497112DOI Listing